JFA
RXRX icon

JNBA Financial Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

JNBA Financial Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$476 Hold
155
– – ﹤0.01% 800
2025
Q4 		$634 Hold
155
– – ﹤0.01% 767
2025
Q3 		$757 Buy
+155
New +$814 ﹤0.01% 628
2025
Q2 		– Sell
-2,450
Closed -$13K – 686
2025
Q1 		$13K Buy
+2,450
New +$17.9K ﹤0.01% 429

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JNBA Financial Advisors's RXRX Position: Q1 2026 in Review

JNBA Financial Advisors held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 155 shares worth $476. The position accounts for ﹤0.01% of the portfolio, ranked #800.

JNBA Financial Advisors first reported a position in RXRX in Q1 2025 and has held it in 4 quarters since. The position peaked at $13K in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • JNBA Financial Advisors held 155 shares of Recursion Pharmaceuticals worth $476 as of Q1 2026.
  • JNBA Financial Advisors left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of JNBA Financial Advisors's portfolio in Q1 2026, its #800 holding.
  • JNBA Financial Advisors first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • JNBA Financial Advisors's Recursion Pharmaceuticals position peaked at $13K in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on JNBA Financial Advisors's 13F filing for Q1 2026, filed 23 Apr 2026.